36.2. Analysis.

Comparison 36: VX‐152 (300 mg twice daily) plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily) versus placebo plus tezacaftor (100 mg once daily) plus ivacaftor (150 mg twice daily), Outcome 2: FEV1 % predicted (relative change from baseline)